VivoSeq
Ophthalmology

Dry Age Related Macular Degeneration

6

Pipeline Programs↗

0

Active Trials↗

4

Companies Involved↗

Dry Age Related Macular Degeneration is an early-stage landscape with 6 programs across 4 companies. The most active players are Gemini Therapeutics, Inc., Johnson & Johnson, Astellas. 1 therapy is approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

29/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

G

Gemini Therapeutics, Inc.

1 program

Phase 1Johnson & Johnson logo

Johnson & Johnson

1 program

Phase 1Astellas logo

Astellas

1 program

Phase 2Teva logo

Teva

1 program

Approved

Pipeline

Programs by Phase

Analysis

Modality Breakdown

67%

Small molecule

2 of 3 classified programs — the dominant modality here.

33%ALL OTHERSGene therapy133%

Small molecule leads; the ring shows all 3 classified programs, each share of the total. Modality classified for 100% of 7 pipeline programs.

Analysis

Trial Status

6

clinical trials

Completed5 · 83%
Unknown status1 · 17%

Clinical Trials

Trial Activity

6 trials

First in Human Study to Evaluate the Safety and Tolerability of GEM103 in Geographic Atrophy Secondary to Dry Age Related Macular Degeneration
Completed·GGemini Therapeutics, Inc.·Phase 1·NCT04246866·12 enrolled
Treatment of Advanced Dry Age Related Macular Degeneration With AAVCAGsCD59
Completed·Johnson & Johnson logoJohnson & Johnson·Phase 1·NCT03144999·17 enrolled
Safety Study of a Topical Treatment for Dry Age Related Macular Degeneration
Completed·MMacuCLEAR, Inc.·Phase 1·NCT01922128·20 enrolled
Safety and Tolerability of Sub-retinal Transplantation of hESC Derived RPE (MA09-hRPE) Cells in Patients With Advanced Dry Age Related Macular Degeneration
Completed·Astellas logoAstellas·Phase 1/2·NCT01344993·13 enrolled
An Open-label Single Ascending Dose Safety and Tolerability Clinical Trial of PST-611 in Subjects With Dry Age-related Macular Degeneration
Completed·EEyevensys·Phase 1·NCT07024732·8 enrolled
Treatment of Dry Age Related Macular Degeneration Disease With Retinal Pigment Epithelium Derived From Human Embryonic Stem Cells
Unknown status·CChinese Academy of Sciences·Phase 1/2·NCT03046407·10 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)